eISSN: 2084-9869
ISSN: 1233-9687
Polish Journal of Pathology
Current issue Archive Manuscripts accepted About the journal Supplements Editorial board Abstracting and indexing Subscription Contact Instructions for authors Ethical standards and procedures
SCImago Journal & Country Rank
3/2021
vol. 72
 
Share:
Share:
more
 
 
abstract:
Original paper

The relationship between PD-L1 expression and tumor driver gene mutations and survival in non small cell lung carcinoma

Kin Iong Chan
1
,
Hong Ting Vong
1
,
Wai Kuou Chu
2
,
Kun Cheng
3
,
Xue Yun Zhong
4
,
Jian Ming Wen
1

1.
Department of Pathology, Kiang Wu Hospital, Macao Special Administrative Region, China
2.
Department of Surgery, Kiang Wu Hospital, Macao Special Administrative Region, China
3.
Department of Internal Medicine, Kiang Wu Hospital, Macao Special Administrative Region, China
4.
Department of Pathology, Medical School of Jinan University, Guangzhou 510632, China
Pol J Pathol 2021; 72 (3): 222-228
Online publish date: 2022/01/19
View full text
Get citation
ENW
EndNote
BIB
JabRef, Mendeley
RIS
Papers, Reference Manager, RefWorks, Zotero
AMA
APA
Chicago
Harvard
MLA
Vancouver
 
To explore the relationship between PD-L1 expression and gene mutations and survival. PD L1, ALK and MET protein expression were detected by immunohistochemistry, and EGFR gene mutation by RT-PCR in 209 cases of NSCLC. The correlations between PD-L1 expression and gene mutations, clinicopathological features and survival was analyzed. PD-L1 was expressed in 99/209 cases (47.4%) of NSCLC, including score 1 (≥ 1% to < 5%) 23 cases (11%), score 2 (≥ 5% to < 50%) 36 cases (17.2%), and score 3 (> 50%) 40 cases (19.1%). There were 89 cases (42.6%) of EGFR mutation, 12 (5.7%) of ALK and 90 (43.1%) of MET protein positive. PD-L1 positive expression occurred more frequently in men and non-adenocarcinoma, and was negatively correlated with EGFR mutation and histological differentiation of NSCLC. PD-L1 expression was concordant in primary and metastatic cancers. There was no any effect of PD-L1 expression on overall survival of patients with NSCLC. These results suggested that PD-L1 expression is not an independent risk factor for survival of patients with NSCLC. Because of mutual complementarities of PD-L1 expression and EGFR mutation in NSCLC, both should be simultaneously detected for the patients to achieve eligible treatments.
keywords:

NSCLC, PD-L1, EGFR; survival

Quick links
© 2022 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.